Targeting MCL-1 sensitizes FLT3-ITD-positive leukemias to cytotoxic therapies

Stefan Kasper(Essen University Hospital), Thomas Fischer(University Hospital Magdeburg)

Blood Cancer Journal

March 9, 2012

10.1038/bcj.2012.5

Cited by 85

Related Papers

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

|New England Journal of Medicine|2016|5.1k

Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial

|The Lancet|2019|2.6k

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

|Oral Oncology|2018|802

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

|The Lancet Oncology|2017|431

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

|The Lancet|2023|319